A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Study summary

The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedIMGN901 and Carboplatin and Etoposide

The study team can explain what participation involves.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 18, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?48 U.S. locations

Locations may change over time.

Who runs it?ImmunoGen, Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: ImmunoGen, Inc.
Interventions being studied: Drug: IMGN901; Drug: Carboplatin and Etoposide

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Small cell lung cancer (SCLC)→

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patients must be 18 years old
Patients must have been diagnosed with small-cell lung cancer (SCLC) and extensive disease
ECOG performance status of 0, 1, or 2
No prior systemic chemotherapy for the treatment of SCLC

Reasons someone may not be able to joinExclusion criteria

\- Pregnant or lactating females

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Arizona Cancer Center @ UMC NorthTucson, Arizona
UCLA Oncology CenterLos Angeles, California
St. Joseph's HospitalOrange, California
UCLA HematologyPasadena, California
UCLA Oncology ClinicSanta Monica, California
UCLA Santa Clarita Valley Cancer CenterValencia, California
UCLA Oncology CenterWestlake Village, California
Yale Medical CenterNew Haven, Connecticut
Sibley Memorial HospitalWashington D.C., District of Columbia
Holy Cross Hospital Bienes Comprehensive Cancer CenterFort Lauderdale, Florida
University of FloridaGainesville, Florida
Anne Arundel Medical CenterAnnapolis, Maryland

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 18, 2018. Always confirm current availability with the study team.

View original record ↗